Sponsored by:
From Macro to Micro
A Leap in Small Molecule Sensitivity
Small molecule drugs represent ~60% of the total global pharmaceuticals market and, on average, accounted for ~64% of FDA Novel Drug Approvals during the period 2019 - 2024. Traditionally Octet® biolayer interferometry (BLI) has been regarded as not being sensitive enough to detect small molecules and, therefore, surface plasmon resonance (SPR) has been seen as the primary technique to determine real-time kinetics and affinity values for small molecules.
In this application note we analyze the binding interactions of sulfonamide-based small molecules with carbonic anhydrase II using the newly released Octet® R8e. Analysis of the observed kinetics and affinity values shows excellent agreement with previously published SPR data and highlights the feasibility of Octet® R8e BLI as a reliable tool for studying small molecule interactions with macromolecules in various research and development applications.
